Topics

ElMinda Ltd Product Pipeline Analysis, 2019 Update [Published by Global Data] Prices from USD $660

04:42 EST 4 Dec 2019 | BioPortfolio Reports

Summary


ElMinda Ltd ElMinda is a medical technology company that develops tools for the diagnosis, monitoring, and treatment of brainrelated disorders. The company offers brain network activation technology that combines electroencephalography and eventrelated potential testing procedures with machinelearning and advanced algorithms, and largepopulation databases to provide a way to see how the brain's neural networks are activated and extract unique data about brain function and health. Its technology is used in various areas, including mild traumatic brain injury, traumatic brain injury, major depressive disorder, Parkinson's disease, multiple sclerosis, ADHD, and mild cognitive impairment. The company has operations in Israel and the US. ElMinda is headquartered in Herzliya, Israel.


This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.


The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


Scope:


The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

The report analyzes all pipeline products in development for the company ElMinda Ltd

The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status

The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date

The report provides detailed description of products in development, technical specification and functions

The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.


Reasons to Buy:


Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

To formulate effective Research Development strategies

Develop marketentry and market expansion strategies

Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio


Note: Some sections may be missing if data is unavailable for the company

Original Article: ElMinda Ltd Product Pipeline Analysis, 2019 Update [Published by Global Data] Prices from USD $660

NEXT ARTICLE

More From BioPortfolio on "ElMinda Ltd Product Pipeline Analysis, 2019 Update [Published by Global Data] Prices from USD $660"

Quick Search

Relevant Topics

Anxiety Disorders
Anxiety is caused by stress. It is a natural reaction, and is beneficial in helping us deal with tense situations and pressure. It is deterimental when is becomes an excessive, irrational dread of everyday situations. The most common types of anxiety di...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...